The JUPITER registry: One‐year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation

Objectives We present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation (AR). Background Transcatheter aortic valve replacement (TAVR) is routine in high‐risk patients with aortic stenosis but is not recommended for AR. The JenaV...

Full description

Saved in:
Bibliographic Details
Published inCatheterization and cardiovascular interventions Vol. 91; no. 7; pp. 1345 - 1351
Main Authors Silaschi, Miriam, Conradi, Lenard, Wendler, Olaf, Schlingloff, Friederike, Kappert, Utz, Rastan, Ardawan J, Baumbach, Hardy, Holzhey, David, Eichinger, Walter, Bader, Ralf, Treede, Hendrik
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.06.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives We present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation (AR). Background Transcatheter aortic valve replacement (TAVR) is routine in high‐risk patients with aortic stenosis but is not recommended for AR. The JenaValve™ (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism. Methods The JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012‐2015, 30 patients with AR were enrolled. Results Mean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One‐year Kaplan‐Meier survival was 79.9%, one‐year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow‐up. Conclusions The JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One‐year results using the JenaValve for AR encourage its use for this indication.
AbstractList We present 1-year outcomes of the post-market registry of a next-generation transcatheter heart valve used for aortic regurgitation (AR). Transcatheter aortic valve replacement (TAVR) is routine in high-risk patients with aortic stenosis but is not recommended for AR. The JenaValve™ (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism. The JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012-2015, 30 patients with AR were enrolled. Mean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One-year Kaplan-Meier survival was 79.9%, one-year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow-up. The JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One-year results using the JenaValve for AR encourage its use for this indication.
ObjectivesWe present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation (AR).BackgroundTranscatheter aortic valve replacement (TAVR) is routine in high‐risk patients with aortic stenosis but is not recommended for AR. The JenaValve™ (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism.MethodsThe JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012‐2015, 30 patients with AR were enrolled.ResultsMean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One‐year Kaplan‐Meier survival was 79.9%, one‐year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow‐up.ConclusionsThe JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One‐year results using the JenaValve for AR encourage its use for this indication.
Objectives We present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation (AR). Background Transcatheter aortic valve replacement (TAVR) is routine in high‐risk patients with aortic stenosis but is not recommended for AR. The JenaValve™ (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism. Methods The JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012‐2015, 30 patients with AR were enrolled. Results Mean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One‐year Kaplan‐Meier survival was 79.9%, one‐year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow‐up. Conclusions The JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One‐year results using the JenaValve for AR encourage its use for this indication.
Abstract Objectives We present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation (AR). Background Transcatheter aortic valve replacement (TAVR) is routine in high‐risk patients with aortic stenosis but is not recommended for AR. The JenaValve™ (JenaValve Technology GmbH, Munich, Germany) overcomes technical challenges in AR patients through a leaflet clipping mechanism. Methods The JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere Aortic Stenosis oR Aortic Insufficiency (JUPITER) Registry is a European study to evaluate safety and effectiveness of this THV. From 2012‐2015, 30 patients with AR were enrolled. Results Mean age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery. No annular rupture or coronary ostia obstruction occurred. Mortality at 30 days was 10.0% (3/30). Combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). Rate of permanent pacemaker implantation was 3.8% (1/26). One‐year Kaplan‐Meier survival was 79.9%, one‐year combined efficacy was 73.1% (19/30). No further strokes were observed during 1 year of follow‐up. Conclusions The JenaValve overcomes technical challenges of TAVR in AR through a clipping mechanism. We report satisfactory outcomes of a multicenter registry using the JenaValve for predominant AR, as rate of THV embolization, residual AR and permanent pacemaker implantation was low. One‐year results using the JenaValve for AR encourage its use for this indication.
Author Rastan, Ardawan J
Treede, Hendrik
Holzhey, David
Kappert, Utz
Wendler, Olaf
Schlingloff, Friederike
Silaschi, Miriam
Baumbach, Hardy
Eichinger, Walter
Bader, Ralf
Conradi, Lenard
Author_xml – sequence: 1
  givenname: Miriam
  orcidid: 0000-0001-7293-5516
  surname: Silaschi
  fullname: Silaschi, Miriam
  email: Miriam.silaschi@uk-halle.de
  organization: University Hospital Halle (Saale)
– sequence: 2
  givenname: Lenard
  surname: Conradi
  fullname: Conradi, Lenard
  organization: University Heart Center Hamburg
– sequence: 3
  givenname: Olaf
  surname: Wendler
  fullname: Wendler, Olaf
  organization: King's College Hospital London
– sequence: 4
  givenname: Friederike
  surname: Schlingloff
  fullname: Schlingloff, Friederike
  organization: Asklepios Klinik St. Georg
– sequence: 5
  givenname: Utz
  surname: Kappert
  fullname: Kappert, Utz
  organization: University Heart Center Dresden
– sequence: 6
  givenname: Ardawan J
  surname: Rastan
  fullname: Rastan, Ardawan J
  organization: Center of Cardiovascular Diseases Rotenburg a. d. Fulda
– sequence: 7
  givenname: Hardy
  surname: Baumbach
  fullname: Baumbach, Hardy
  organization: Robert‐Bosch‐Krankenhaus
– sequence: 8
  givenname: David
  surname: Holzhey
  fullname: Holzhey, David
  organization: Heart Center Leipzig, University of Leipzig
– sequence: 9
  givenname: Walter
  surname: Eichinger
  fullname: Eichinger, Walter
  organization: Klinikum München Bogenhausen GmbH
– sequence: 10
  givenname: Ralf
  surname: Bader
  fullname: Bader, Ralf
  organization: Asklepios Klinik St. Georg
– sequence: 11
  givenname: Hendrik
  surname: Treede
  fullname: Treede, Hendrik
  organization: University Hospital Halle (Saale)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29171730$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1uFDEQRi2UiPzAggsgS2xgMYntcbttdmgIIVGkIDSR2Flud_WMo257YruDZscRuAF34yQx6QkLJFZVUr16qtJ3hPZ88IDQK0pOKCHs1Nr2hNXzmjxDh7RibFYz8W1v11PFxQE6SumWEKIEU8_RAVO0pvWcHKJfyzXgy5svF8uzrzjCyqUct-_xtYffP35uwUQcxmzDAAmHDudofDIbZ02PTYjZWXxv-nvAbtj0xmeTXfB4TM6vsMEJbPAtXoGHOE0e963Ja8gQ8bro807QhfhkLFeMceUm2Qu035k-wctdPUY3n86Wi8-zq-vzi8WHq5nlVJFZw2xTgexs21YdZR2tiOSNbbgEwmRrWymauhNCzrkhQrVUNMKAZFZxxa2V82P0dvJuYrgbIWU9uGShL19BGJOmSkjOuSBVQd_8g96GMfpynWZlXAmuqCjUu4myMaQUodOb6AYTt5oS_Sc1XVLTj6kV9vXOODYDtH_Jp5gKcDoB310P2_-b9GLxcVI-APEYptQ
CitedBy_id crossref_primary_10_1016_j_hlc_2019_04_012
crossref_primary_10_1002_ccd_27840
crossref_primary_10_3390_jcm11030499
crossref_primary_10_1053_j_ro_2023_10_002
crossref_primary_10_15420_icr_2021_19
crossref_primary_10_1016_j_jaccas_2021_01_021
crossref_primary_10_1148_rg_2019180059
crossref_primary_10_2174_1573403X15666181205105821
crossref_primary_10_1016_j_jscai_2022_100530
crossref_primary_10_1016_j_heliyon_2023_e16734
crossref_primary_10_15420_ecr_2021_12
crossref_primary_10_1016_j_case_2020_05_015
crossref_primary_10_2217_fca_2021_0065
crossref_primary_10_1111_jocs_16237
crossref_primary_10_1007_s11886_020_01338_6
crossref_primary_10_1093_icvts_ivz005
crossref_primary_10_1093_eurheartj_ehaa799
crossref_primary_10_4244_EIJ_D_18_01048
crossref_primary_10_1016_j_jaccas_2021_03_004
crossref_primary_10_1016_j_jcin_2023_07_018
crossref_primary_10_1016_j_acvd_2022_12_003
crossref_primary_10_1016_j_carrev_2019_03_021
crossref_primary_10_1016_j_jcin_2020_01_216
crossref_primary_10_3389_fcvm_2018_00085
crossref_primary_10_1007_s15027_023_3067_9
crossref_primary_10_1002_ccd_29379
crossref_primary_10_1016_j_iccl_2021_06_008
crossref_primary_10_1016_j_shj_2023_100164
crossref_primary_10_1080_24748706_2021_2010849
crossref_primary_10_1111_jocs_16238
crossref_primary_10_1007_s12055_023_01678_2
crossref_primary_10_1177_0885066620918776
crossref_primary_10_1016_j_amjcard_2023_01_011
crossref_primary_10_3390_jcm13102997
crossref_primary_10_1016_j_jcin_2019_10_021
crossref_primary_10_15212_CVIA_2023_0033
crossref_primary_10_1002_ehf2_14832
crossref_primary_10_2174_1381612826666200413083746
crossref_primary_10_15420_icr_2018_37_1
crossref_primary_10_23736_S0021_9509_22_11260_7
crossref_primary_10_1007_s00392_019_01422_0
crossref_primary_10_3389_fcvm_2023_1098348
crossref_primary_10_5761_atcs_oa_19_00325
crossref_primary_10_1016_j_jacc_2021_02_038
crossref_primary_10_1016_j_carrev_2022_08_010
crossref_primary_10_3390_jcm11175181
crossref_primary_10_1536_ihj_20_398
crossref_primary_10_1016_S0140_6736_24_00062_X
crossref_primary_10_3390_jcdd10070279
crossref_primary_10_1016_j_athoracsur_2022_09_016
crossref_primary_10_1080_24748706_2020_1719446
crossref_primary_10_1007_s11886_019_1205_x
crossref_primary_10_1055_a_1922_6387
crossref_primary_10_3389_fcvm_2019_00179
crossref_primary_10_1016_j_cjca_2023_11_023
crossref_primary_10_3390_jcdd9070224
Cites_doi 10.1016/j.jcin.2014.04.016
10.1097/HCO.0b013e3283655bb5
10.1093/ejcts/ezu041
10.1093/ejcts/ezu290
10.1016/j.jacc.2010.12.005
10.1097/00005650-199603000-00003
10.1016/S0195-668X(03)00201-X
10.1016/j.jacc.2013.01.018
10.4244/EIJV10I6A127
10.1016/j.jacc.2014.02.536
10.1093/ejcts/ezs129
10.1016/j.jtcvs.2013.05.029
10.1007/s12181-009-0183-4
10.1016/j.jcin.2014.05.014
10.1055/s-0035-1551676
10.1093/ejcts/ezs455
10.1016/j.jacc.2015.03.034
10.1093/ejcts/ezs297
10.1161/CIRCULATIONAHA.109.927921
10.4244/EIJV8SQA16
10.1016/j.jcin.2015.08.022
ContentType Journal Article
Copyright 2017 Wiley Periodicals, Inc.
2018 Wiley Periodicals, Inc.
Copyright_xml – notice: 2017 Wiley Periodicals, Inc.
– notice: 2018 Wiley Periodicals, Inc.
DBID NPM
AAYXX
CITATION
7T5
7U9
H94
K9.
7X8
DOI 10.1002/ccd.27370
DatabaseName PubMed
CrossRef
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed
AIDS and Cancer Research Abstracts
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1522-726X
EndPage 1351
ExternalDocumentID 10_1002_ccd_27370
29171730
CCD27370
Genre article
Journal Article
GrantInformation_xml – fundername: JenaValve Technologies GmbH
GroupedDBID ---
.3N
.GA
05W
0R~
10A
1L6
1OC
29B
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
SUPJJ
SV3
TEORI
UB1
V2E
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
XPP
XV2
~IA
~WT
.GJ
.Y3
31~
53G
AAQQT
ACBWZ
AZFZN
FEDTE
HF~
HVGLF
NPM
ZGI
AAYXX
CITATION
7T5
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c4190-b2cb5e8fcdd5f12f15084bcb48e028dcd86b7f66834a069d16b6ae82c9494cc83
IEDL.DBID DR2
ISSN 1522-1946
IngestDate Fri Aug 16 11:57:07 EDT 2024
Thu Oct 10 22:18:17 EDT 2024
Fri Aug 23 00:30:54 EDT 2024
Wed Oct 16 00:50:04 EDT 2024
Sat Aug 24 00:59:51 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords transapical
aortic regurgitation
TAVI
Language English
License 2017 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4190-b2cb5e8fcdd5f12f15084bcb48e028dcd86b7f66834a069d16b6ae82c9494cc83
Notes Funding information
M. Silaschi and L. Conradi contributed equally to this manuscript
JenaValve Technologies GmbH
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
ORCID 0000-0001-7293-5516
PMID 29171730
PQID 2053564916
PQPubID 986345
PageCount 7
ParticipantIDs proquest_miscellaneous_1968444605
proquest_journals_2053564916
crossref_primary_10_1002_ccd_27370
pubmed_primary_29171730
wiley_primary_10_1002_ccd_27370_CCD27370
PublicationCentury 2000
PublicationDate June 1, 2018
PublicationDateYYYYMMDD 2018-06-01
PublicationDate_xml – month: 06
  year: 2018
  text: June 1, 2018
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle Catheterization and cardiovascular interventions
PublicationTitleAlternate Catheter Cardiovasc Interv
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2015; 47
2013; 28
2013; 43
2012; 8 Suppl Q
2013; 61
2015; 63
2015; 65
2003; 24
2010; 122
2013; 146
2014; 46
2011; 57
2014; 63
2009; 3
2014; 7
2015; 8
2012; 42
2014; 10
2012; 41
1996; 34
29894586 - Catheter Cardiovasc Interv. 2018 Jun;91(7):1352-1353
e_1_2_9_20_1
e_1_2_9_11_1
e_1_2_9_22_1
e_1_2_9_10_1
e_1_2_9_21_1
e_1_2_9_13_1
e_1_2_9_12_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_9_1
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_17_1
e_1_2_9_16_1
e_1_2_9_19_1
e_1_2_9_18_1
References_xml – volume: 61
  start-page: 1577
  year: 2013
  end-page: 1584
  article-title: Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation
  publication-title: J Am Coll Cardiol
– volume: 8 Suppl Q
  start-page: Q88
  year: 2012
  end-page: Q93
  article-title: JenaValve
  publication-title: EuroIntervention
– volume: 47
  start-page: 39
  year: 2015
  end-page: 45
  article-title: Single‐centre experience with next‐generation devices for transapical aortic valve implantation
  publication-title: Eur J Cardiothorac Surg
– volume: 34
  start-page: 220
  year: 1996
  end-page: 233
  article-title: A 12‐Item Short‐Form Health Survey: construction of scales and preliminary tests of reliability and validity
  publication-title: Medical Care
– volume: 28
  start-page: 632
  year: 2013
  end-page: 638
  article-title: Aortic root rupture: implications of catheter‐guided aortic valve replacement
  publication-title: Curr Opin Cardiol
– volume: 57
  start-page: 253
  year: 2011
  end-page: 269
  article-title: Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium
  publication-title: J Am Coll Cardiol
– volume: 122
  start-page: 43
  year: 2010
  end-page: 47
  article-title: Prognostic implications of mitral regurgitation in patients with severe aortic regurgitation
  publication-title: Circulation
– volume: 3
  start-page: 199
  year: 2009
  end-page: 206
  article-title: Positionspapier zur kathetergeführten Aortenklappenintervention
  publication-title: Kardiologe
– volume: 7
  start-page: 1168
  year: 2014
  end-page: 1174
  article-title: Initial German experience with transapical implantation of a second‐generation transcatheter heart valve for the treatment of aortic regurgitation
  publication-title: J Am Coll Cardiol Intv
– volume: 7
  start-page: 1159
  year: 2014
  end-page: 1167
  article-title: Transapical transcatheter aortic valve for severe aortic regurgitation: expanding the limits
  publication-title: J Am Coll Cardiol Intv
– volume: 46
  start-page: 808
  year: 2014
  end-page: 816
  article-title: The German Aortic Valve Registry: 1‐year results from 13,680 patients with aortic valve disease
  publication-title: Eur J Cardiothorac Surg
– volume: 10
  start-page: 739
  year: 2014
  end-page: 745
  article-title: CoreValve implantation for severe aortic regurgitation: a multicentre registry
  publication-title: EuroIntervention
– volume: 43
  start-page: 505
  year: 2013
  end-page: 511
  article-title: Transapical aortic valve implantation: mid‐term outcome from the SOURCE registry
  publication-title: Eur J Cardiothorac Surg
– volume: 8
  start-page: 1842
  year: 2015
  end-page: 1849
  article-title: Transfemoral implantation of a fully repositionable and retrievable transcatheter valve for noncalcified pure aortic regurgitation
  publication-title: J Am Coll Cardiol Interv
– volume: 42
  start-page: 1
  year: 2012
  end-page: 44
  article-title: Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS)
  publication-title: Eur J Cardiothorac Surg
– volume: 63
  start-page: e57
  year: 2014
  end-page: 185
  article-title: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
  publication-title: J Am Coll Cardiol
– volume: 41
  start-page: e131
  year: 2012
  end-page: e138
  article-title: Transapical transcatheter aortic valve implantation using the JenaValve™ system: acute and 30‐day results of the multicentre CE‐mark study
  publication-title: Eur J Cardiothorac Surg
– volume: 65
  start-page: 2173
  year: 2015
  end-page: 2180
  article-title: Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from. The GARY registry
  publication-title: J Am Coll Cardiol
– volume: 146
  start-page: e40
  year: 2013
  end-page: e41
  article-title: Transapical aortic valve (JenaValve) implantation for severe aortic insufficiency and aortic aneurysm
  publication-title: J Thorac Cardiovasc Surg
– volume: 63
  start-page: 258
  year: 2015
  end-page: 269
  article-title: Cardiac surgery in Germany during 2014: A report on behalf of the German Society for Thoracic and Cardiovascular Surgery
  publication-title: Thorac Cardiovasc Surg
– volume: 24
  start-page: 1231
  year: 2003
  end-page: 1243
  article-title: A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease
  publication-title: Eur Heart J
– ident: e_1_2_9_20_1
  doi: 10.1016/j.jcin.2014.04.016
– ident: e_1_2_9_17_1
  doi: 10.1097/HCO.0b013e3283655bb5
– ident: e_1_2_9_14_1
  doi: 10.1093/ejcts/ezu041
– ident: e_1_2_9_19_1
  doi: 10.1093/ejcts/ezu290
– ident: e_1_2_9_11_1
  doi: 10.1016/j.jacc.2010.12.005
– ident: e_1_2_9_12_1
  doi: 10.1097/00005650-199603000-00003
– ident: e_1_2_9_4_1
  doi: 10.1016/S0195-668X(03)00201-X
– ident: e_1_2_9_6_1
  doi: 10.1016/j.jacc.2013.01.018
– ident: e_1_2_9_5_1
  doi: 10.4244/EIJV10I6A127
– ident: e_1_2_9_3_1
  doi: 10.1016/j.jacc.2014.02.536
– ident: e_1_2_9_9_1
  doi: 10.1093/ejcts/ezs129
– ident: e_1_2_9_16_1
  doi: 10.1016/j.jtcvs.2013.05.029
– ident: e_1_2_9_10_1
  doi: 10.1007/s12181-009-0183-4
– ident: e_1_2_9_8_1
  doi: 10.1016/j.jcin.2014.05.014
– ident: e_1_2_9_22_1
  doi: 10.1055/s-0035-1551676
– ident: e_1_2_9_2_1
  doi: 10.1093/ejcts/ezs455
– ident: e_1_2_9_13_1
  doi: 10.1016/j.jacc.2015.03.034
– ident: e_1_2_9_18_1
  doi: 10.1093/ejcts/ezs297
– ident: e_1_2_9_15_1
  doi: 10.1161/CIRCULATIONAHA.109.927921
– ident: e_1_2_9_7_1
  doi: 10.4244/EIJV8SQA16
– ident: e_1_2_9_21_1
  doi: 10.1016/j.jcin.2015.08.022
SSID ssj0009629
Score 2.5005226
Snippet Objectives We present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation (AR). Background...
We present 1-year outcomes of the post-market registry of a next-generation transcatheter heart valve used for aortic regurgitation (AR). Transcatheter aortic...
Abstract Objectives We present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation (AR)....
ObjectivesWe present 1‐year outcomes of the post‐market registry of a next‐generation transcatheter heart valve used for aortic regurgitation...
OBJECTIVESWe present 1-year outcomes of the post-market registry of a next-generation transcatheter heart valve used for aortic regurgitation...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1345
SubjectTerms aortic regurgitation
Aortic stenosis
Aortic valve
Electrocardiography
Embolization
Implantation
Regurgitation
Safety
Stenosis
Surgery
TAVI
transapical
Title The JUPITER registry: One‐year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fccd.27370
https://www.ncbi.nlm.nih.gov/pubmed/29171730
https://www.proquest.com/docview/2053564916
https://search.proquest.com/docview/1968444605
Volume 91
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEB5KH4ov2npNrbKKD77k9GSzZ7PRJzm1lEJVigf6IIS95SC2yaFJBH3yJ_gP_G_-Emc2ySlVBPEtkOwlOzM73-zlG4BnUhPHt8jirBScVqvKWKFniD1CWaV0mqWadnRP3sijhTg-m51twMvxLkzPD7FecCPLCPM1Gbg2zf4Vaai1boK-N6N4PUkzOs51cHpFHZXLkKEM3ROPsTNyZBWa8v11yeu-6A-AeR2vBodzeAs-jF3tz5l8mnStmdivv7E4_ue_bMPNAYiyV73m7MCGr27D1smw1X4HfqACsePFO5zaThmlb6CscC_Y28r__Pb9C9oHq7sW2_ENq0vWhrTjK5I40zXVyVCFP3v28WJ1rvvrTRWjQ_ZLpllDUbhjy0B5Hd6E8oFCFuXMKMt2O1SAoHqsEXvRXS4HUvG7sDh8_X5-FA_ZHGIr6L664dbMvCqtc7My4SUR0QtjjVAeMY6zTkmTlVKqVOipzF0ijdSoMjYXubBWpfdgs6or_wCY4y7zM7SB3JUiMWmu-VRbjESVsQh5dARPR7kWq560o-jpmXmBQ12EoY5gb5R4MdhtU3Ciu5ECMXMET9av0eJoG0VXvu6aAucsJQTtJ0dwv9eUdSsco98EJ80Ingd5_735Yj4_CA-7__7pQ7iBeE31J9X2YLO97PwjxESteRyU_xc2DgpA
link.rule.ids 315,783,787,1378,27938,27939,46310,46734
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB5VRQIuvCmGAgviwMVpst6s14gLSqlCaQqqGqkXZO3LEQLsqLGR4MRP4B_w3_glzKztVAUhIW6W7H14Z2bnm318A_BEauL4FmmcFoLTalURK_QMsUcoq5RO0kTTju7sUE7nYv9kfLIBz_u7MC0_xHrBjSwjzNdk4LQgvXPGGmqtG6DzTTFgv4DmnhBz_u7RGXlUJkOOMnRQPMbuyJ5XaMh31kXPe6M_IOZ5xBpczt5VeNd3tj1p8mHQ1GZgv_7G4_i_f3MNrnRYlL1olec6bPjyBlycdbvtN-EH6hDbn7_F2e2IUQYHSgz3jL0p_c9v37-gibCqqbEhv2JVweqQeXxJQme6ojoZavFnz95_Wn7U7Q2nktE5-wXTbEWBuGOLwHod3oTygUUWRc0o0XbdVYC4uq8Re9GcLjpe8Vsw33t5PJnGXUKH2Aq6sm64NWOvCuvcuBjxgrjohbFGKI8wx1mnpEkLKVUi9FBmbiSN1Kg1NhOZsFYlt2GzrEp_B5jjLvVjNIPMFWJkkkzzobYYjCpjEfXoCB73gs2XLW9H3jI08xyHOg9DHcF2L_K8M91VzonxRgqEzRE8Wr9Go6OdFF36qlnlOG0pIWhLOYKtVlXWrXAMgEc4b0bwNAj8783nk8lueLj7758-hEvT49lBfvDq8PU9uIzwTbUH17Zhsz5t_H2ESLV5ECzhF8ArDlw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRaq48H6kLWAQBy7Z7jpex4ET2rIqhZaqYqUekCw_VwhIVt2kUjnxE_gH_Dd-CWMn2aogJMQtUuJHPDOeb_z4BuApV4Hjm-Vp7hkNq1U-FegZUodQVgiV5ZkKO7oHh3xvxvZPxidr8KK_C9PyQ6wW3IJlxPk6GPjC-p0L0lBj7AB9b47x-hXGEaUERHR8wR1V8JiiDP0TTbE3vKcVGtKdVdHLzugPhHkZsEaPM70OH_q-tgdNPg2aWg_M199oHP_zZ27AtQ6Jkpet6tyENVfego2Dbq_9NvxADSL7syOc245JyN8Q0sI9J-9K9_Pb93M0EFI1NbbjlqTypI55xxdB5ERVoU6COnzmyMcvi8-qvd9UknDKfk4UWYYw3JJ55LyOb2L5yCGLgiYhzXbdVYCouq8Re9GczjtW8Tswm756P9lLu3QOqWHhwrqmRo-d8MbasR9RH5jomTaaCYcgxxoruM495yJjasgLO-KaK9QZU7CCGSOyu7BeVqW7D8RSm7sxGkFhPRvprFB0qAyGokIbxDwqgSe9XOWiZe2QLT8zlTjUMg51Atu9xGVnuEtJA98NZwiaE3i8eo0mF_ZRVOmqZilx0hKMhQ3lBO61mrJqhWL4O8JZM4FnUd5_b15OJrvxYfPfP30EG0e7U_n29eGbLbiK2E20p9a2Yb0-bdwDxEe1fhjt4Bd87g0C
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+JUPITER+registry%3A+One%E2%80%90year+outcomes+of+transapical+aortic+valve+implantation+using+a+second+generation+transcatheter+heart+valve+for+aortic+regurgitation&rft.jtitle=Catheterization+and+cardiovascular+interventions&rft.au=Silaschi%2C+Miriam&rft.au=Conradi%2C+Lenard&rft.au=Wendler%2C+Olaf&rft.au=Schlingloff%2C+Friederike&rft.date=2018-06-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1522-1946&rft.eissn=1522-726X&rft.volume=91&rft.issue=7&rft.spage=1345&rft.epage=1351&rft_id=info:doi/10.1002%2Fccd.27370&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-1946&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-1946&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-1946&client=summon